Emerging real-world and population-based data are refining how clinicians understand outcomes in diffuse large B-cell lymphoma (DLBCL), underscoring the critical role of patient characteristics, particularly age, immune status, and comorbidities, across both standard and novel treatment settings.
One analysis focused on the impact of age in patients receiving CD19-directed CAR-T therapy, a potentially curative approach for relapsed or refractory disease. Although DLBCL predominantly affects older adults, patients aged ≥75 years have historically been underrepresented in clinical trials.1 Using the TriNetX database, Khan et al compared outcomes between older patients (≥75 years) and a younger cohort (18-65 years), employing propensity score matching to balance baseline characteristics.1
After matching, 241 patients were included in each group. Notably, survival outcomes were comparable regardless of age. There were no significant differences in overall survival (OS) at 1 year (hazard ratio [HR], 0.89; 95% CI, 0.63-1.26) or 3 years (HR, 1.00; 95% CI, 0.74-1.36), suggesting that advanced age alone does not compromise long-term outcomes following CAR-T therapy.1
Equally important, older patients did not experience higher toxicity. In fact, rates of cytokine release syndrome and infections within 100 days were lower in patients aged ≥75 years, whereas the incidence of immune effector cell–associated neurotoxicity syndrome was similar between groups.1 These findings challenge traditional assumptions about treatment tolerance in older patients and support broader consideration of CAR-T therapy in carefully selected individuals, irrespective of age.
Complementing these findings, a large population-based study by Haddad et al examined outcomes in a distinct and rare subtype: human herpesvirus 8 (HHV8)-positive DLBCL.2 Drawing on National Cancer Database data from 2004 to 2023, investigators analyzed 262 patients, providing the most comprehensive dataset to date for this disease.
The study confirmed known epidemiologic patterns, including a predominance in younger male patients and frequent nodal presentation. Despite its aggressive classification, median OS exceeded 10 years, with approximately 60% of patients alive at 5 years. However, outcomes varied significantly depending on key clinical factors.2
Age again emerged as a major determinant of survival, but with a different pattern than seen in the CAR-T setting. Patients aged ≥60 years had more than double the risk of death compared with younger individuals. HIV status also independently predicted worse outcomes, with HIV-positive patients experiencing a similarly increased risk of mortality.2 These findings highlight the impact of immune dysfunction on disease progression in HHV8-driven lymphomas.
Comorbidity burden further influenced prognosis, as did access to treatment. Patients who did not receive systemic therapy had significantly poorer survival, emphasizing the importance of active management even in rare or challenging subtypes.2
Taken together, these studies illustrate the nuanced role of patient demographic factors in DLBCL. Although advanced age alone should not preclude the use of intensive or novel therapies such as CAR-T, other variables, including HIV status, comorbidities, and access to treatment, remain critical determinants of outcomes, particularly in biologically distinct subtypes. These findings reinforce the importance of individualized treatment decisions and highlight the need to move beyond age-based assumptions toward more comprehensive risk assessment in lymphoma care.